• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Should Guardant Health’s (GH) Role in ENHERTU’s Japan Approval Require Action From Investors?

    Simply Wall St·04/07/2026 21:14:18
    Listen to the news
    • In late March 2026, Guardant Health announced that its InfinityAI real-world evidence platform was used alongside clinical trial data to support Japan’s approval of Daiichi Sankyo’s ENHERTU for treating HER2-positive advanced or recurrent solid cancers refractory or intolerant to standard therapies.
    • This use of InfinityAI highlights how Guardant’s clinicogenomic data and artificial intelligence can help regulators assess outcomes in genomic subpopulations that are difficult to enroll in traditional trials.
    • Next, we’ll examine how InfinityAI’s role in supporting a Japanese drug approval could reshape Guardant Health’s investment narrative around real-world evidence.

    Invest in the nuclear renaissance through our list of 93 elite nuclear energy infrastructure plays powering the global AI revolution.

    Guardant Health Investment Narrative Recap

    To own Guardant Health, you need to believe that liquid biopsy, AI driven analytics, and real world evidence can support a large, durable oncology and screening franchise despite ongoing losses and cash burn. The InfinityAI role in ENHERTU’s Japanese approval may reinforce confidence in the biopharma and data businesses in the near term, but it does not meaningfully change the central risk around high spending, negative free cash flow, and potential future dilution.

    The March 24 partnership with Verana Health is especially relevant here, because it also centers on combining clinicogenomic and real world data to support drug development and clinical decision making. Taken together with the ENHERTU approval support, it reinforces the idea that Guardant’s data and AI platforms could become more important to pharma partners, which may matter for upcoming data and partnership milestones even as the core Shield screening ramp and payer adoption remain the key swing factors.

    Yet, despite this momentum in AI and real world evidence, investors still need to be aware of how persistent cash burn and the risk of future dilution could...

    Read the full narrative on Guardant Health (it's free!)

    Guardant Health's narrative projects $2.1 billion revenue and $107.1 million earnings by 2029.

    Uncover how Guardant Health's forecasts yield a $130.64 fair value, a 46% upside to its current price.

    Exploring Other Perspectives

    GH 1-Year Stock Price Chart
    GH 1-Year Stock Price Chart

    Some of the lowest tier analysts were assuming about US$1.7 billion of revenue and only US$95.2 million of earnings by 2029, which is a much more cautious view than investors who are focused on InfinityAI’s regulatory role and broader data partnerships, so it is worth comparing these more pessimistic forecasts with your own expectations before deciding how much weight to give this latest news.

    Explore 5 other fair value estimates on Guardant Health - why the stock might be worth as much as 94% more than the current price!

    The Verdict Is Yours

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    Searching For A Fresh Perspective?

    Every day counts. These free picks are already gaining attention. See them before the crowd does:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.